Irina Vetter

Dr. Irina Vetter

School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RCRebecca C Coll
Rebecca C Coll
ARAvril Robertson
Avril Robertson
JCJae Jin Chae
Jae Jin Chae
SHSarah C Higgins
Sarah C Higgins
RMRaúl Muñoz-Planillo
Raúl Muñoz-Planillo
Luke O'NeillLuke O'Neill
Luke O'Neill

6 September 2017 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
JDJennifer R. Deuis
Jennifer R. Deuis
LDLucie S. Dvorakova
Lucie S. Dvorakova
Irina VetterIrina Vetter
Irina Vetter
Rodents are commonly used to study the pathophysiological mechanisms of pain as studies in humans may be difficult to perform and ethically limited. As pain cannot be directly measured in rodents, many methods that quantify “pain-like” behaviors or nociception have been developed. These behavioral methods can be divided into stimulus-evoked or non-stimulus evoked (spontaneous) nociception, based on whether or not application of an external stimulus is used to elicit a withdrawal response. Stimulus-evoked methods, which include manual and electronic von Frey, Randall-Selitto, and the Hargreaves test, were the first to be developed and continue to be in widespread use. However, concerns over the clinical translatability of stimulus-evoked nociception in recent years has led to the development and increasing implementation of non-stimulus evoked methods, such as grimace scales, burrowing, weight bearing and gait analysis. This review provides an overview, as well as discussion of the advantages and disadvantages, of the most commonly used behavioral methods of stimulus-evoked and non-stimulus-evoked nociception used in rodents.

31 May 2017 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
HSHana Starobova
Hana Starobova
Irina VetterIrina Vetter
Irina Vetter
Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment, and severely affects the quality of life of cancer survivors. Clinically, chemotherapy-induced peripheral neuropathy presents as deficits in sensory, motor, and autonomic function which develop in a glove and stocking distribution due to preferential effects on longer axons. The pathophysiological processes are multi-factorial and involve oxidative stress, apoptotic mechanisms, altered calcium homeostasis, axon degeneration and membrane remodeling as well as immune processes and neuroinflammation. This review focusses on the commonly used antineoplastic substances oxaliplatin, cisplatin, vincristine, docetaxel and paclitaxel which interfere with the cancer cell cycle – leading to cell death and tumor degradation – and cause severe acute and chronic peripheral neuropathies. We discuss drug mechanism of action and pharmacokinetic disposition relevant to the development of peripheral neuropathy, the epidemiology and clinical presentation of chemotherapy-induced neuropathy, emerging insight into genetic susceptibilities as well as current understanding of the pathophysiology and treatment approaches.

1 April 2012 in Pharmacological Reviews
Verified
Journal Article
Open access
PDF file
RLRichard J. Lewis
Richard J. Lewis
Dutertre SebastienDutertre Sebastien
Dutertre Sebastien
Irina VetterIrina Vetter
Irina Vetter
MCMacdonald Christie
Macdonald Christie
Conopeptides are a diverse group of recently evolved venom peptides used for prey capture and/or defense. Each species of cone snails produces in excess of 1000 conopeptides, with those pharmacologically characterized (∼0.1%) targeting a diverse range of membrane proteins typically with high potency and specificity. The majority of conopeptides inhibit voltage- or ligand-gated ion channels, providing valuable research tools for the dissection of the role played by specific ion channels in excitable cells. It is noteworthy that many of these targets are found to be expressed in pain pathways, with several conopeptides having entered the clinic as potential treatments for pain [e.g., pyroglutamate1-MrIA (Xen2174)] and one now marketed for intrathecal treatment of severe pain [ziconotide (Prialt)]. This review discusses the diversity, pharmacology, structure-activity relationships, and therapeutic potential of cone snail venom peptide families acting at voltage-gated ion channels (ω-, μ-, μO-, δ-, ι-, and κ-conotoxins), ligand-gated ion channels (α-conotoxins, σ-conotoxin, ikot-ikot, and conantokins), G-protein-coupled receptors (ρ-conopeptides, conopressins, and contulakins), and neurotransmitter transporters (χ-conopeptides), with expanded discussion on the clinical potential of sodium and calcium channel inhibitors and α-conotoxins. Expanding the discovery of new bioactives using proteomic/transcriptomic approaches combined with high-throughput platforms and better defining conopeptide structure-activity relationships using relevant membrane protein crystal structures are expected to grow the already significant impact conopeptides have had as both research probes and leads to new therapies.

24 March 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
Dutertre SebastienDutertre Sebastien
Dutertre Sebastien
AJAi-Hua JIN
Ai-Hua JIN
Irina VetterIrina Vetter
Irina Vetter
Brett HamiltonBrett Hamilton
Brett Hamilton
Kartik SunagarKartik Sunagar
Kartik Sunagar
RLRichard J. Lewis
Richard J. Lewis
Venomous animals are thought to inject the same combination of toxins for both predation and defence, presumably exploiting conserved target pharmacology across prey and predators. Remarkably, cone snails can rapidly switch between distinct venoms in response to predatory or defensive stimuli. Here, we show that the defence-evoked venom of Conus geographus contains high levels of paralytic toxins that potently block neuromuscular receptors, consistent with its lethal effects on humans. In contrast, C. geographus predation-evoked venom contains prey-specific toxins mostly inactive at human targets. Predation- and defence-evoked venoms originate from the distal and proximal regions of the venom duct, respectively, explaining how different stimuli can generate two distinct venoms. A specialized defensive envenomation strategy is widely evolved across worm, mollusk and fish-hunting cone snails. We propose that defensive toxins, originally evolved in ancestral worm-hunting cone snails to protect against cephalopod and fish predation, have been repurposed in predatory venoms to facilitate diversification to fish and mollusk diets.

24 February 2010 in Amino Acids
Verified
Journal Article
Closed access
PDF file
Irina VetterIrina Vetter
Irina Vetter
JDJasmine L. Davis
Jasmine L. Davis
LRLachlan Rash
Lachlan Rash
RARaveendra Anangi
Raveendra Anangi
MMMehdi Mobli
Mehdi Mobli
Glenn KingGlenn King
Glenn King